124 related articles for article (PubMed ID: 36971130)
1. The effectiveness and mechanical properties of chemotherapy-impregnated cement in Ewing sarcoma.
Goldin AN; Healey RM
J Orthop Res; 2023 Nov; 41(11):2540-2546. PubMed ID: 36971130
[TBL] [Abstract][Full Text] [Related]
2. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.
Boehme KA; Nitsch J; Riester R; Handgretinger R; Schleicher SB; Kluba T; Traub F
Int J Oncol; 2016 Nov; 49(5):2135-2146. PubMed ID: 27665785
[TBL] [Abstract][Full Text] [Related]
4. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
Zhang J; Huang Y; Sun Y; He A; Zhou Y; Hu H; Yao Y; Shen Z
BMC Cancer; 2019 Dec; 19(1):1168. PubMed ID: 31791278
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
[TBL] [Abstract][Full Text] [Related]
6. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin loaded PMMA: mechanical properties, surface analysis and effects on Saos-2 cell culture.
Özben H; Eralp L; Baysal G; Cort A; Sarkalkan N; Özben T
Acta Orthop Traumatol Turc; 2013; 47(3):184-92. PubMed ID: 23748618
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Paioli A; Luksch R; Fagioli F; Tamburini A; Cesari M; Palmerini E; Abate ME; Marchesi E; Balladelli A; Pratelli L; Ferrari S
J Chemother; 2014 Feb; 26(1):49-56. PubMed ID: 24091100
[TBL] [Abstract][Full Text] [Related]
9. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
[TBL] [Abstract][Full Text] [Related]
11. Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma.
Lucari B; Tallis E; Sutton VR; Porea T
Pediatr Hematol Oncol; 2023 May; 40(4):422-428. PubMed ID: 36125320
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy for osteosarcoma and Ewing sarcoma.
Meyers PA
Am Soc Clin Oncol Educ Book; 2015; ():e644-7. PubMed ID: 25993235
[TBL] [Abstract][Full Text] [Related]
13. Dramatic response to Cisplatin window therapy in a boy with advanced metastatic ewing sarcoma.
Trizzino A; Ziino O; Parafioriti A; Podda M; Tropia S; Luksch R; D'Angelo P
J Pediatr Hematol Oncol; 2013 Aug; 35(6):478-81. PubMed ID: 23892353
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
Unland R; Clemens D; Heinicke U; Potratz JC; Hotfilder M; Fulda S; Wardelmann E; Frühwald MC; Dirksen U
Anticancer Drugs; 2015 Sep; 26(8):843-51. PubMed ID: 26053276
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
Lu E; Ryan CW; Bassale S; Lim JY; Davis LE
Oncologist; 2020 Feb; 25(2):150-155. PubMed ID: 32043790
[TBL] [Abstract][Full Text] [Related]
17. Curettage, phenolization, and cementation in paediatric Ewing's sarcoma with a complete radiological response to neoadjuvant chemotherapy.
Jamshidi K; Ramezan Shirazi M; Bagherifard A; Mirzaei A
Int Orthop; 2019 Feb; 43(2):467-473. PubMed ID: 30099643
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
[TBL] [Abstract][Full Text] [Related]
19. Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity.
Sonnemann J; Kahl M; Siranjeevi PM; Blumrich A; Blümel L; Becker S; Wittig S; Winkler R; Krämer OH; Beck JF
J Cancer Res Clin Oncol; 2016 Jan; 142(1):17-26. PubMed ID: 26055805
[TBL] [Abstract][Full Text] [Related]
20. Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis.
Machado I; Yoshida A; Morales MGN; Abrahão-Machado LF; Navarro S; Cruz J; Lavernia J; Parafioriti A; Picci P; Llombart-Bosch A
Ann Diagn Pathol; 2018 Jun; 34():1-12. PubMed ID: 29661713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
